Squamous NSCLC Treatments Incorporating Immunotherapy Combinations

Key Considerations for Managing IO Toxicity in NSCLC

Julie Brahmer, MD, and David P. Carbone, MD, PhD, share insights on managing toxicities of immune checkpoint inhibitor therapies in non–small cell lung cancer.

Identifying Situations Where CTLA-4 Addition Improves NSCLC Outcomes

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and chemotherapy in patients with non–small cell lung cancer in the PD-L1–low setting.

Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of single agent vs doublet immunotherapy in the PD-L1–low setting.

Discontinuation Did Not Reduce CheckMate 9LA Regimen’s Efficacy in NSCLC

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.

CheckMate 9LA Outcomes Stand Out in PD-L1 Negative and Squamous NSCLC

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Pembrolizumab/Chemo Continues to Impress in NSCLC With 5-Year Updates

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung cancer setting in the second article of a 2-part series.

Five-Year Data Shows CheckMate 9LA Regimen Maintains Survival in NSCLC

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.

Participants Discuss Rare Dual Immunotherapy AE Experiences in NSCLC

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, talked with event participants about adverse events they have observed in their patients after using immune checkpoint inhibitors in the second article of a 2-part series.

Dual ICI Considered for a Patient With NSCLC and Low PD-L1

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, discusses the use of immunotherapy combinations based on patients PD-L1 expression in the first article of a 2-part series.

POLL: What Would You Do for a Patient With Metastatic NSCLC?

In the case of a woman with metastatic non–small cell lung cancer, answer question of what you would do in terms of treatment and management, as well as questions about your practice.

Choosing Appropriate Patients for Dual Immunotherapy/Chemotherapy in NSCLC

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed which patients with non–small cell lung cancer should receive immunotherapy-containing regimens. This is the second of 2 articles based on this event.

Patient Characteristics Influence Choice of Chemo/IO Regimen in NSCLC

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed the importance of patient characteristics and biomarkers in choosing an immunotherapy-containing regimen for patients with non–small cell lung cancer, particularly if their PD-L1 expression is low. This is the first of 2 articles based on this event.

Patient Selection Considerations for CheckMate 9LA Regimen in NSCLC

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed with participants which patients are candidates for chemoimmunotherapy for advanced non–small cell lung cancer. This is the second of 2 articles based on this event.

Reviewing 3-Year Updated Data From CheckMate 9LA for NSCLC

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed 3-year data on overall survival and subgroup analysis for the CheckMate 9LA trial of ipilimumab, nivolumab, and 2 cycles of chemotherapy.

Advanced Squamous NSCLC Survival Improved With Chemoimmunotherapy Regardless of PD-L1 Expression

During a live virtual event, Adam M. Schoenfeld, MD, discussed results of the KEYNOTE-407 trial of patients with advanced squamous non–small cell lung cancer in terms of PD-L1 expression. This is the second of 2 articles based on this event.

Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLC

During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.

Ipilimumab/Nivolumab Improves Survival in NSCLC Regardless of PD-L1 Status

Martin Dietrich, MD, PhD, discusses the study design and results of the CheckMate 9LA trial of ipilimumab and nivolumab for patients with non–small cell lung cancer.